Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Prog Urol ; 25(3): 128-37, 2015 Mar.
Artigo em Francês | MEDLINE | ID: mdl-25595615

RESUMO

INTRODUCTION: Diagnosis, localization of recurrence in the management of prostate cancer patients with increasing concentrations of tumor serum markers is crucial for treatment planning of the patients. The present review describes the role of prostate MRI and (18) Fcholine PET/computed tomography (CT) in tumor detection and extent, when there is a suspicion of residual or recurrent disease after treatment of prostate cancer. METHOD: A systematic review of the literature was performed by searching in the PUB MED/MEDLINE database searching for articles in French or English published between the last 12years. RESULTS: In patient with a clinical suspicion of recurrence after treatment for prostate cancer, imaging can be used to distinguish between local recurrence and metastatic disease. (11)C-choline PET/CT and pelvic multiparametric MR imaging (mp MRI) are complementary in this indication. In this paper, the current status of imaging techniques used for the staging of patients with suspected locally recurrent or metastatic disease in patients treated for prostate cancer were reviewed. CONCLUSION: Mp MRI of the prostate may be valuable imaging modality for the detection and localization of local recurrence. C-choline PET/CT offers an advantage in detecting metastatic disease to lymph node and bone.


Assuntos
Recidiva Local de Neoplasia/diagnóstico , Neoplasias da Próstata/diagnóstico , Colina/análogos & derivados , Radioisótopos de Flúor , Humanos , Imageamento por Ressonância Magnética , Masculino , Imagem Multimodal , Tomografia por Emissão de Pósitrons , Neoplasias da Próstata/terapia , Tomografia Computadorizada por Raios X
2.
Transpl Infect Dis ; 16(1): 135-40, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24383613

RESUMO

Trichosporon species are rare etiologic agents of invasive fungal infection in solid organ transplant (SOT) recipients. We report 2 well-documented cases of Trichosporon inkin invasive infection in SOT patients. We also conducted a detailed literature review of Trichosporon species infections in this susceptible population. We gathered a total of 13 cases of Trichosporon species infections. Any type of organ transplantation can be complicated by Trichosporon infection. Bloodstream infections and disseminated infections were the most common clinical presentations. Liver recipients with bloodstream or disseminated infections had poor prognoses. Although the most common species was formerly called Trichosporon beigelii, this species name should no longer be used because of the changes in the taxonomy of this genus resulting from the advent of molecular approaches, which were also used to identify the strains isolated from our patients. Antifungal susceptibility testing highlights the possibility of multidrug resistance. Indeed, Trichosporon has to be considered in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. Voriconazole seems to be the best treatment option.


Assuntos
DNA Fúngico/análise , Empiema/imunologia , Rejeição de Enxerto/prevenção & controle , Transplante de Coração , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Pneumopatias Fúngicas/imunologia , Transplante de Pulmão , Mediastinite/imunologia , Pericardite/imunologia , Trichosporon/genética , Tricosporonose/imunologia , Adulto , Antifúngicos/uso terapêutico , DNA Intergênico/análise , DNA Ribossômico/análise , Farmacorresistência Fúngica , Empiema/diagnóstico , Empiema/tratamento farmacológico , Humanos , Pneumopatias Fúngicas/diagnóstico , Pneumopatias Fúngicas/tratamento farmacológico , Masculino , Mediastinite/diagnóstico , Mediastinite/tratamento farmacológico , Testes de Sensibilidade Microbiana , Pericardite/diagnóstico , Pericardite/tratamento farmacológico , Derrame Pleural/diagnóstico , Derrame Pleural/tratamento farmacológico , Derrame Pleural/imunologia , Pirimidinas/uso terapêutico , Análise de Sequência de DNA , Triazóis/uso terapêutico , Tricosporonose/diagnóstico , Tricosporonose/tratamento farmacológico , Voriconazol , Adulto Jovem
3.
Cancer Radiother ; 17(2): 81-4, 2013 Apr.
Artigo em Francês | MEDLINE | ID: mdl-23562380

RESUMO

Low-dose rate brachytherapy has some radiobiological advantages compared to external beam radiotherapy: subletal damages repair during irradiation leading to a relative protection of healthy tissues; no tumor cell repopulation, cell cycle redistribution and a low oxygen enhancement ratio. High dose rate and pulsed dose rate modalities allow an optimization of dose distribution by varying the dwell times over the different dwell positions. Because of the use of afterloaders, they also offer a better radioprotection of the staff. High dose rate and pulsed dose rate treatments seem to offer the same results as low-dose rate brachytherapy, particularly in cervix carcinoma. For high dose rate brachytherapy, schedules must be designed according to the linear-quadratic model. In pulsed dose rate brachytherapy, pulse dose and time intervals must also be derived from the linear-quadratic model, but half-time repair must be taken into account.


Assuntos
Braquiterapia , Braquiterapia/efeitos adversos , Braquiterapia/métodos , Ciclo Celular/efeitos da radiação , Radioisótopos de Cobalto/uso terapêutico , Dano ao DNA , Fracionamento da Dose de Radiação , Feminino , Humanos , Radioisótopos de Índio/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Radioisótopos de Irídio/uso terapêutico , Masculino , Neoplasias/radioterapia , Tratamentos com Preservação do Órgão , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Eficiência Biológica Relativa
4.
Antimicrob Agents Chemother ; 45(6): 1937-8, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11353659

RESUMO

Itraconazole diffusion in sputum was studied in 11 cystic fibrosis patients with allergic bronchopulmonary aspergillosis. There was a high interindividual variability in sputum itraconazole concentration and sputum/serum drug concentration ratio. Three children had sputum drug concentrations before oral administration that were lower than the itraconazole MIC at which 90% of Aspergillus fumigatus strains were inhibited, although their serum drug concentrations were within the therapeutic range.


Assuntos
Aspergilose Broncopulmonar Alérgica/tratamento farmacológico , Fibrose Cística/complicações , Fibrose Cística/metabolismo , Itraconazol/uso terapêutico , Escarro/química , Adolescente , Aspergilose Broncopulmonar Alérgica/complicações , Aspergillus fumigatus/efeitos dos fármacos , Criança , Pré-Escolar , Humanos , Itraconazol/sangue , Itraconazol/metabolismo , Testes de Sensibilidade Microbiana
5.
J Clin Oncol ; 15(2): 701-11, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9053496

RESUMO

PURPOSE: To conduct a multicenter phase II study of a concomitant combination of chemotherapy and radiotherapy followed by surgery, where feasible, in patients with nonmetastatic esophageal tumor, stratified on operability at diagnosis. METHODS: Each cycle consisted of fluorouracil (5FU) 800 mg/m2/d by continuous intravenous (IV) infusion on days 1 to 5, cisplatin (CDDP) 50 mg/m2/d IV bolus on days 1 and 8, hydroxyurea (HU) 1.5 or 2 g/d orally on days 8 to 12 and concomitant radiotherapy 20 Gy in 10 fractions over 12 days. All patients were to receive two cycles on days 1 and 22. If feasible, surgery was performed 3 to 6 weeks after cycle two completion. Otherwise, a third cycle was administered. RESULTS: Eighty-eight patients were included between September 1990 and September 1993. Of the 47 operable patients, 41 (87%) underwent surgery and 38 (81%) had a complete resection. No residual primary tumor was found in the surgical specimen in 17 cases (36%), and only microscopic foci in 13 (28%). Two-year overall and disease-free survival probabilities were 51% (95% confidence interval [CI]; 37 to 65) and 43% (95% CI, 28 to 57), respectively. Among the 41 inoperable patients, 12 (29%) became operable. Seven (17%) had complete resection, two incomplete resection, and three exploratory surgery. Two-year overall and disease-free survival probabilities were 29% (95% CI, 15 to 43) and 27% (95% CI, 13 to 40), respectively. Five deaths occurred during chemoradiotherapy, six postoperatively and four in patients with evidence of cancer. Five late complications (one myelopathy) were observed. CONCLUSION: Despite a high histologic response rate in initially operable patients, overall survival was similar to that observed in other preoperative chemoradiation series because of substantial toxicity.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Esofágicas/terapia , Idoso , Antimetabólitos Antineoplásicos/administração & dosagem , Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Intervalo Livre de Doença , Esquema de Medicação , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/radioterapia , Neoplasias Esofágicas/cirurgia , Feminino , Fluoruracila/administração & dosagem , Humanos , Hidroxiureia/administração & dosagem , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Radioterapia Adjuvante , Análise de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA